JP2012516900A5 - - Google Patents

Download PDF

Info

Publication number
JP2012516900A5
JP2012516900A5 JP2011549296A JP2011549296A JP2012516900A5 JP 2012516900 A5 JP2012516900 A5 JP 2012516900A5 JP 2011549296 A JP2011549296 A JP 2011549296A JP 2011549296 A JP2011549296 A JP 2011549296A JP 2012516900 A5 JP2012516900 A5 JP 2012516900A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
alkylaryl
cancer
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011549296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516900A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/023391 external-priority patent/WO2010091306A1/en
Publication of JP2012516900A publication Critical patent/JP2012516900A/ja
Publication of JP2012516900A5 publication Critical patent/JP2012516900A5/ja
Pending legal-status Critical Current

Links

JP2011549296A 2009-02-05 2010-02-05 ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ Pending JP2012516900A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15003109P 2009-02-05 2009-02-05
US61/150,031 2009-02-05
PCT/US2010/023391 WO2010091306A1 (en) 2009-02-05 2010-02-05 Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015159619A Division JP2016034946A (ja) 2009-02-05 2015-08-12 ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ

Publications (2)

Publication Number Publication Date
JP2012516900A JP2012516900A (ja) 2012-07-26
JP2012516900A5 true JP2012516900A5 (enExample) 2013-03-21

Family

ID=42115803

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011549296A Pending JP2012516900A (ja) 2009-02-05 2010-02-05 ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ
JP2015159619A Pending JP2016034946A (ja) 2009-02-05 2015-08-12 ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015159619A Pending JP2016034946A (ja) 2009-02-05 2015-08-12 ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ

Country Status (9)

Country Link
US (2) US20110312916A1 (enExample)
EP (2) EP2393827B1 (enExample)
JP (2) JP2012516900A (enExample)
CN (1) CN102686600A (enExample)
AU (1) AU2010210422A1 (enExample)
BR (1) BRPI1008745A2 (enExample)
CA (1) CA2761389A1 (enExample)
ES (1) ES2552087T3 (enExample)
WO (1) WO2010091306A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
US20110312916A1 (en) 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
DE102011083725A1 (de) 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
SG11201401471PA (en) * 2011-11-30 2014-08-28 Astrazeneca Ab Combination treatment of cancer
WO2013096907A1 (en) * 2011-12-22 2013-06-27 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using p13k/mtor inhibitors
WO2014102833A2 (en) * 2012-12-31 2014-07-03 Hetero Research Foundation Process for abiraterone acetate
CA2898573A1 (en) * 2013-01-18 2014-07-24 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
US9714266B2 (en) 2013-02-21 2017-07-25 Bayer Pharma Aktiengesellschaft Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3)
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
EP3514147B1 (en) * 2013-04-04 2022-08-03 University of Maryland, Baltimore Steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
EP3033088A4 (en) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
CN104017045B (zh) * 2014-06-23 2016-01-13 广州艾格生物科技有限公司 甾体cyp17抑制剂的新型药物前体及其应用、制备方法
CN105646637B (zh) * 2014-11-28 2018-12-14 四川海思科制药有限公司 一种阿比特龙衍生物及其制备方法和医药用途
CN107188922B (zh) * 2016-03-14 2019-12-20 四川海思科制药有限公司 一种阿比特龙衍生物的盐及其制备方法和医药用途
CN107188921A (zh) * 2016-03-15 2017-09-22 四川海思科制药有限公司 阿比特龙衍生物的制备方法及其新固态形式和用途
CN107365343A (zh) * 2016-05-12 2017-11-21 四川海思科制药有限公司 一种苯并咪唑雄甾衍生物及其制备方法和医药用途
ES2697706R1 (es) * 2016-06-01 2019-02-08 Ind Chimica Srl Proceso Para La Preparación De Galeterona.
ITUA20164043A1 (it) * 2016-06-01 2017-12-01 Ind Chimica Srl Processo per la preparazione di 3β-idrossi-17-(1H-benzimidazol-1-il)androsta-5,16-diene
CN106220705A (zh) * 2016-07-25 2016-12-14 厦门市瑞思医药科技有限公司 一种2’‑(n,n,n‑三甲基氯化铵基)乙酸阿比特龙酯的合成方法
CN109846826A (zh) * 2019-01-25 2019-06-07 湖南华腾制药有限公司 醋酸阿比特龙柔性脂质体及其制备方法
JP7644713B2 (ja) 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
WO2021100019A1 (en) 2019-11-22 2021-05-27 Suven Life Sciences Limited Prodrugs of abiraterone
WO2022122042A1 (zh) * 2020-12-12 2022-06-16 上海喀露蓝科技有限公司 阿比特龙衍生物及其制备方法
JP2024506382A (ja) 2021-02-15 2024-02-13 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
EP4294513A1 (en) 2021-02-19 2023-12-27 Mevion Medical Systems, Inc. Gantry for a particle therapy system
CN113061154B (zh) * 2021-03-25 2022-07-08 天津海润家和创新医药研究有限责任公司 新型注射用阿比特龙衍生物的制备方法和用途

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2664423A (en) 1952-03-12 1953-12-29 Searle & Co 4-(cyclopentanopolyhydrophenanthr-17-yl) imidazoles and derivatives thereof
GB972672A (en) * 1960-01-14 1964-10-14 Ciba Ltd Pharmaceutical preparations containing compounds of the androstane series
US3060174A (en) * 1960-01-14 1962-10-23 Ciba Geigy Corp Esters of the androstane series and process for their manufacture
US3313809A (en) 1965-03-05 1967-04-11 Sterling Drug Inc Steroido[21, 20-d]isoxazoles
US3317520A (en) 1965-03-05 1967-05-02 Sterling Drug Inc Steroido[20, 21-c]pyrazoles and intermediates
DE1493169A1 (de) * 1965-09-03 1969-06-04 Schering Ag Verfahren zur Herstellung von 5 beta-Bisnorcholanderivaten
US3480621A (en) 1967-01-17 1969-11-25 Phytogen Prod Inc Steroid ketal
CH621803A5 (enExample) 1974-08-08 1981-02-27 Siphar Sa
JPS563000Y2 (enExample) 1976-07-27 1981-01-23
JPS563000A (en) * 1979-06-20 1981-01-13 Green Cross Corp:The Water-soluble cholesterol derivative
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4469689A (en) * 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
IT1216687B (it) 1988-04-01 1990-03-08 Boehringer Biochemia Srl Complessi di platino (ii), loro preparazione e impiego come antitumorali.
US5028726A (en) 1990-02-07 1991-07-02 The University Of Vermont And State Agricultural College Platinum amine sulfoxide complexes
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
DK0786469T3 (da) 1990-06-11 2006-07-10 Gilead Sciences Inc Nukleinsyreligander
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5300294A (en) 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5385936A (en) 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
AU637247B2 (en) 1990-08-01 1993-05-20 Merrell Dow Pharmaceuticals Inc. 4-amino-delta4-steroids and their use as 5alpha-reductase inhibitors
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
US5264427A (en) 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
DK0633893T3 (da) * 1992-03-31 2000-04-17 Btg Int Ltd 17-Substituerede steroider, der er nyttige ved cancerbehandling
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5237064A (en) 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
EP0641208B1 (en) 1992-05-20 2000-08-02 Merck & Co. Inc. 4-azasteroid 5-alpha-reductase inhibitors
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
DE4232681C2 (de) 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
EP0706581A4 (en) 1993-04-30 1999-02-10 Pacific Northwest Research Fou DNA PROFILES INDICATORS OF CELLULAR OXYREDUCTION POTENTIAL AND CANCER RISK
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
JP4105761B2 (ja) 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン（マクロライド）の半合成類似体免疫調節剤
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
JP3745772B2 (ja) 1993-12-17 2006-02-15 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤として有用なラパマイシン誘導体
US5637310A (en) 1993-12-20 1997-06-10 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
JP3226545B2 (ja) 1995-06-09 2001-11-05 ノバルティス・アクチエンゲゼルシャフト ラパマイシン誘導体
CA2233084A1 (en) 1995-10-19 1997-04-24 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-.alpha.-reductase inhibitors
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
EP1070725B9 (en) 1998-04-10 2011-02-23 Mitsubishi Chemical Corporation Solid dispersion containing sialic acid derivative
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP1027885B1 (en) 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
EP1212331B1 (en) 1999-08-24 2004-04-21 Ariad Gene Therapeutics, Inc. 28-epirapalogs
AU7491400A (en) 1999-09-17 2001-04-17 Abbott Gmbh & Co. Kg Kinase inhibitors as therapeutic agents
DK1955700T3 (da) 1999-09-30 2011-05-23 Harbor Biosciences Inc Terapeutisk behandling af androgenreceptor-betingede lidelser
OA12124A (en) 1999-12-23 2006-05-05 Pfizer Prod Inc Pharmmaceutical compositions providing enhanced drug concentrations.
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
AU2002251266A1 (en) 2001-04-10 2002-10-28 Merck Sharp And Dohme Limited Inhibitors of akt activity
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20030054053A1 (en) 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
WO2003031400A1 (en) 2001-10-12 2003-04-17 Johns Hopkins University Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3
SE0103424D0 (sv) 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
PL371593A1 (en) 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
JP4451136B2 (ja) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
ES2333318T3 (es) 2002-08-12 2010-02-19 Bend Research, Inc. Composiciones farmaceuticas de medicamentos con estructura semiordenada y de polimero.
AU2003270087B2 (en) 2002-09-03 2009-04-23 Georgetown University Akt inhibitors, pharmaceutical compositions, and uses thereof
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
US7399764B2 (en) 2002-10-30 2008-07-15 Merck & Co., Inc. Inhibitors of Akt activity
TW200500360A (en) 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
EP1622616B1 (en) 2003-04-24 2011-06-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2004233827B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
DE602004023838D1 (de) 2003-04-24 2009-12-10 Merck & Co Inc Hemmer der akt aktivität
CA2522262A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
US7439268B2 (en) * 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use
WO2005014023A1 (en) 2003-07-29 2005-02-17 Dompe' Pha.R.Ma S.P.A. Pharmaceutical combination of g-csf and plgf useful for blood stem cell
WO2005018562A2 (en) 2003-08-22 2005-03-03 University Of Virginia Patent Foundation Blockade of mtor to prevent a hormonal adaptive response
US7605120B2 (en) 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
MXPA06005578A (es) 2003-11-17 2006-08-11 Pfizer Prod Inc Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
US20070185152A1 (en) 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
US20050239751A1 (en) * 2004-03-26 2005-10-27 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
WO2005098446A2 (en) 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
NZ550222A (en) 2004-04-08 2010-09-30 Topotarget As Diphenyl ox-indol-2-one compounds and their use in the treatment of cancer
JP2007532551A (ja) 2004-04-09 2007-11-15 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害剤
ATE499364T1 (de) 2004-04-09 2011-03-15 Merck Sharp & Dohme Hemmer der akt aktivität
US7604947B2 (en) 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
US20060013873A1 (en) 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
EP1812406B1 (en) 2004-09-30 2018-09-12 Janssen Pharmaceutica N.V. Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
CA2597456A1 (en) 2005-02-14 2006-08-31 Merck & Co., Inc. Inhibitors of akt activity
ATE482969T1 (de) 2005-03-02 2010-10-15 Univ Maryland 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androst - 5,16-dien zur anwendung in der behandlung von prostata-erkrankungen
WO2006110638A2 (en) 2005-04-12 2006-10-19 Merck & Co., Inc. Inhibitors of akt activity
MX2007015578A (es) 2005-06-10 2008-03-06 Merck & Co Inc Inhibidores de la actividad akt.
EP1934603A4 (en) 2005-09-19 2010-01-06 Univ Johns Hopkins BIOMARKER FOR PROSTATE CANCER
EP2385053B1 (en) 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermediates for the preparation of fused bicyclic mTOR inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
JP5156644B2 (ja) 2006-01-25 2013-03-06 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー 不飽和ｍＴＯＲ阻害剤
US7943732B2 (en) 2006-06-05 2011-05-17 Intrexon Corporation AKT ligands and polynucleotides encoding AKT ligands
DK2049500T3 (da) 2006-07-06 2011-12-12 Array Biopharma Inc Cyclopenta [d]-pyrimidiner som AKT-proteinkinase-inhibitorer
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2008027855A2 (en) 2006-08-30 2008-03-06 Novartis Ag Compositions and methods for modulating mtor signaling
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
DE602007008470D1 (en) 2006-10-17 2010-09-23 Bend Res Inc Off
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
WO2008070823A2 (en) 2006-12-07 2008-06-12 University Of South Florida Substrate-mimetic akt inhibitor
WO2008076918A2 (en) 2006-12-15 2008-06-26 University Of Maryland, Baltimore Anti-cancer agents and androgen inhibition activity compound
US7807393B2 (en) 2007-01-29 2010-10-05 Northwestern University Biomarkers for prostate cancer
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
NZ621972A (en) 2007-03-07 2015-09-25 Abraxis Bioscience Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2008154382A1 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009003136A1 (en) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
US20090047252A1 (en) 2007-06-29 2009-02-19 Gilead Sciences, Inc. Antiviral compounds
TW200940542A (en) 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
GB2470873A (en) 2008-03-12 2010-12-08 Univ Maryland Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
US8785423B2 (en) 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
US9146238B2 (en) 2008-04-16 2015-09-29 The Johns Hopkins University Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
JP2011525535A (ja) 2008-06-24 2011-09-22 武田薬品工業株式会社 ＰＩ３Ｋ／ｍＴＯＲ阻害剤
WO2010089763A2 (en) 2008-06-30 2010-08-12 Reliance Life Sciences Pvt. Ltd. Poly(n-vinyl caprolactam-co-acrylamide) microparticles for controlled release applications
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP2011529080A (ja) 2008-07-24 2011-12-01 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 癌幹細胞を標的とする治療法
CA2735716A1 (en) 2008-09-12 2010-03-18 Dako Denmark A/S Prostate cancer biomarker
US8133724B2 (en) 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
US8841422B2 (en) 2008-09-17 2014-09-23 University Of Maryland, Baltimore Human androgen receptor alternative splice variants
JP2012506898A (ja) 2008-10-31 2012-03-22 ノバルティス アーゲー ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤
CN101607985B (zh) 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
US20110312916A1 (en) 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
GB2479337A (en) 2009-02-05 2011-10-05 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
WO2010104705A1 (en) 2009-03-12 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
ES2873502T3 (es) 2009-03-27 2021-11-03 Bend Res Inc Proceso de secado por pulverización
US8791094B2 (en) 2009-08-07 2014-07-29 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
BR112012012167A2 (pt) 2009-11-13 2017-10-03 Tokai Pharmaceuticals Inc Metabólitos mamíferos de esteróides
EP2545186A1 (en) 2010-03-08 2013-01-16 Regents Of The University Of Minnesota Androgen receptor isoforms and methods
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
US20120028972A1 (en) 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
WO2012129408A2 (en) 2011-03-22 2012-09-27 The Johns Hopkins University Biomarkers for aggressive prostate cancer
JP2014523445A (ja) 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
SG11201401471PA (en) 2011-11-30 2014-08-28 Astrazeneca Ab Combination treatment of cancer
WO2013096907A1 (en) 2011-12-22 2013-06-27 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using p13k/mtor inhibitors

Similar Documents

Publication Publication Date Title
JP2012516900A5 (enExample)
US20250120947A1 (en) Compounds and methods to sensitize cancer cells to cisplatin
RU2425041C2 (ru) Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она
US10577337B2 (en) Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
JP6559719B2 (ja) （ｓ）−６−（（１−アセチルピペリジン−４−イル）アミノ）−ｎ−（３−（３、４−ジヒドロイソキノリン−２（１ｈ）−イル）−２−ヒドロキシプロピル）ピリミジン−４−カルボキサミドの結晶塩
JP2013544261A5 (enExample)
JP2019524883A5 (enExample)
JP2012092149A5 (enExample)
RU2013106754A (ru) Производное фталазинонкетона, способ его получения и его фармацевтическое применение
JP2015511638A5 (enExample)
RU2013156687A (ru) Антагонисты рецептора св1
JP2011068653A5 (enExample)
US20140235568A1 (en) Gemcitabine amide derivative and preparation method and use thereof
JP2009530398A5 (enExample)
CN108025191A (zh) 治疗癌症的方法
JP2014520108A5 (enExample)
WO2018233620A1 (zh) SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途
RU2016116789A (ru) Комбинация энзалутамида и афурезертиба для лечения рака
KR101401220B1 (ko) 방사선 치료 증강제
US9738613B2 (en) Substituted 1,2,3-triazoles as antitumor agents
JP2016523830A5 (enExample)
WO2014046589A1 (en) Means and method for treating solid tumours
RU2016110546A (ru) Комбинированная лекарственная терапия
JP2013525290A5 (enExample)
JP5701387B2 (ja) ベルバミンのジカルボキシミド誘導体、その調製方法及び使用